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Background: In 2007, the treatment of diabetes and its complications in the United States generated at least $116 billion
in direct costs; at least 33% of these costs were linked to the treatment of foot ulcers. Although the team approach to
diabetic foot problems is effective in preventing lower extremity amputations, the costs associated with implementing a
diabetic foot care team are not well understood. An analysis of these costs provides the basis for this report.
Results:Diabetic foot problems impose a major economic burden, and costs increase disproportionately to the severity of
the condition. Compared with diabetic patients without foot ulcers, the cost of care for patients with a foot ulcer is 5.4
times higher in the year after the first ulcer episode and 2.8 times higher in the second year. Costs for the treatment of the
highest-grade ulcers are 8 times higher than for treating low-grade ulcers. Patients with diabetic foot ulcers require more
frequent emergency department visits, are more commonly admitted to hospital, and require longer length of stays.
Implementation of the team approach to manage diabetic foot ulcers within a given region or health care system has been
reported to reduce long-term amputation rates from 82% to 62%. Limb salvage efforts may include aggressive therapy,
such as revascularization procedures and advanced wound healing modalities. Although these procedures are costly, the
team approach gradually leads to improved screening and prevention programs and earlier interventions, and thus seems
to reduce long-term costs.
Conclusions: To date, aggressive limb preservation management for patients with diabetic foot ulcers has not usually been
paired with adequate reimbursement. It is essential to direct efforts in patient-caregiver education to allow early
recognition and management of all diabetic foot problems and to build integrated pathways of care that facilitate timely
access to limb salvage procedures. Increasing evidence suggests that the costs for implementing diabetic foot teams can be
offset over the long-term by improved access to care and reductions in foot complications and in amputation rates.
(J Vasc Surg 2010;52:17S-22S.)Limb preservation team services have been shown to
reduce major limb amputation, but the associated costs are
not well understood or reported. Perhaps this is true be-
cause the burden of preventing amputations is often real-
ized at a critical health care event, such as limb-threatening
infection or acute critical limb ischemia. In many cases,
these diabetic patients are at very high risk for limb loss,
newly consulted for their acute event, and, therefore, in
their highest health-related cost status. An adequate and
comprehensive cost-effectiveness analysis must consider
health states with limb-preserving impact figures and their
relative cost, as it relates to severity of disease and preven-
tion of amputations. Lower extremity amputations contrib-
ute disproportionately to diabetes-related costs.1
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According to the Centers for Disease Control and
Prevention, 7.8% of the United States population had
diabetes in 2007, which equals almost 24 million persons.2
In 2007, diabetes and its complications cost the United
States $174 billion; $116 billion were in direct costs and
$58.3 billion in indirect costs such as loss of productivity,
disability, and premature mortality.3 Peripheral vascular
complications and neurologic complications, which are
closely linked to foot ulceration, accounted for 31% and
24% of the expenses, respectively, and were among the
major contributors to inpatient length of stay.
Foot problems in persons with diabetes have been
recognized as a major health issue since the times of Joslin
and before the advent of insulin. The diabetic foot with
gangrene was one of the leading causes of death from
diabetes, second only to diabetic coma.4 The rate of hospi-
tal discharges for diabetic patients with leg/foot ulcers for
1000 diabetic patients rose from 5.4 in 1980 to 6.9 in
2003.2 Ulcer prevalence among persons aged 44 years
was 6.5/1000 diabetics and it rose progressively to 10.3/
1000 diabetics in individuals aged 75 years. Hospitaliza-
tions for lower extremity amputations rose from 33,000 in
1980 to 71,000 in 2005; however, average length of stay
fell from 35.3 to 10.7 days during the same period.
More than 60% of nontraumatic lower limb amputa-
tions occur in diabetic individuals, and at least 80% of
amputations are preceded by an ulcer. The causative path-
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The progressive additive effects of neuropathy, minor
trauma, ulceration, faulty healing, ischemia, and infection
leading to amputation were first characterized in 1990.5
Early recognition of foot problems and effective interven-
tion along the causative pathways may not only improve
outcomes by reducing major amputations and increasing
quality of life, but also reduce costs related to diabetic foot
complications. Studies on diabetic foot-related health care
costs are sometimes difficult to compare due to dissimilar
health care systems, reimbursement methods, and access to
care.
THE COSTS OF DIABETIC FOOT
The cost of care for diabetic patients with a lower
extremity ulcer is a major economic burden compared with
the management of a patient with diabetes but no ulcer-
ation. Economic factors will play an ever-increasing role
because third-party payers cannot reimburse all therapies
used to treat chronic ulcerations.
A retrospective analysis of insurance claims from a large
population of private employer-sponsored insurance en-
rollees during the period 1991 to 1992,6 analyzed 3013
patients aged 18 to 64 years who had 3524 ulcer episodes.
They were divided into three severity-level categories ac-
cording to Wagner classification: grade 1 or 2, grade 3, and
grade 4 or 5. The average cost for an ulcer episode was
$4595. This study showed incremental resource utilization
in patients with diabetic foot ulcers progressing fromWag-
ner grade 1 to 2 to the highest grades. Wagner grade 1 or 2
ulcer costs averaged $1929, whereas Wagner grade 3 and
grade 4 or 5 ulcer costs averaged $3980 and $15,792,
respectively. Inpatient expenditures accounted for 80% of
the total costs. Poor vascular status was also strongly asso-
ciated with longer in-hospital stays and higher average total
payments.
An analysis of Medicare claims data from 1995 to 1996
showed that expenditures for diabetic foot patients were
three times higher than for the general population
($15,309 vs $5226), yielding a total cost for Medicare in
1995 of $1.5 billion.7 Lower extremity ulcers accounted
for 24% of the overall cost for diabetic population with an
ulcer. Inpatient stays accounted for 73% of increased cost.7
A retrospective nested case-control study demonstrated
that the relative cost of care for diabetic patients with lower
extremity ulcers ranges from 1.5 to 2.4 times higher than
that of diabetic patients without an ulcer in the year before
diagnosis to 5.4 times higher in the year after the ulcer
episode.8 The cost of care for diabetic patients with an ulcer
showed a tendency to return to the non-ulcer group only
after 2 years from the first diagnosis, but was still 2.8 times
higher. Excess cost was $26,490 in ulcer patients during
the year of the ulcer episode and $4927 for diabetic patients
without an ulcer. The excess cost persisted during the
second year after the ulcer episode. The costs for diabetic
foot ulcer patients were $17,245 compared with $5110 for
patients with diabetes but no ulcer. Patients with diabetes
and a lower extremity ulcer had more inpatient days thandiabetic patients without ulcers (6.03 vs 1.46 days), and
this difference was still significant 1 year after the ulcer
episode (4.06 vs 2.61). Diabetic patients with a foot ulcer
during the first year of the study also had more emergency
department visits (0.42 vs 0.18) and more nonemergency
outpatient visits (35.08 vs 13.05).8
Apelqvist et al9 prospectively monitored 314 patients
with an ulcer episode. They documented that 54% of
patients healed in 2 months, 19% healed in 3 to 4 months,
and 27% healed in 5 months. Healing without amputa-
tion averaged $6664, whereas healing by amputation aver-
aged $44,790. Hospitalization costs and topical treatment
of ulcers accounted for most of the costs. For patients that
healed without amputation, 37% and 45% of the total costs
were for hospitalizations and ulcer treatments, and for
patients that healed with amputations, 65% of total costs
were for hospitalizations and 13% for ulcer treatments. The
same group estimated that the long-term costs of diabetic
foot ulcers remain elevated during the first 3 years after
healing of an ulcer.10
A retrospective study of diabetic patients with lower
extremity ulcers revealed an average cost per ulcer episode
of $13,179. Again, there was an increase in cost according
to ulcer depth as evaluated by the Wagner classification
system. Costs associated with a Wagner grade 1 ulcer
averaged $1892, and Wagner grade 4/5 ulcers averaged
$27,721. This study confirmed the high impact of inpatient
stay as being 77% of the overall cost. Progression from
Wagner ulcers with lower grades to higher grades carried an
additional increase in cost of $20,136.11 This study also
confirmed a higher cost per ulcer episode in patients with
poor vascular status. Patients with a diabetic foot ulcer have
an average hospital length of stay that can be 50% higher
than that of patients without an ulcer.12 A synopsis of the
studies evaluating the costs of diabetic foot is reported in
Table I.
Higher grade lesions and peripheral arterial disease not
only lead to higher amputation rates but are also associated
with higher costs of care mainly due to higher hospitaliza-
tion rates and longer length of stay. Once an ulcer is
present, higher costs are projected over a period of 2 to 3
years compared with patients without foot ulcers.
Socioeconomic factors and reduced or absent insurance
coverage can be very important and may thwart access to
limb-preserving procedures. A study of a large cohort of
individuals from 1998 to 2002 showed that nonwhite,
low-income, Medicare and Medicaid patients were more
likely to undergo an amputation for leg ischemia and to
have less access to limb salvage procedures (eg, revascular-
ization) compared with higher income individuals with
private insurances.13 This may be explained by a delay in
diagnosis of critical leg ischemia and limited access to care
involving both primary care and vascular surgeries.
THE LIMB SALVAGE TEAM
It has long been recognized that the complex nature of
diabetic foot pathology is best treated with a team ap-
proach. The group fromNew England Deaconess Hospital
rage e
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regarded as a forerunner of this approach. In 1992,
LoGerfo et al14 published the results of aggressive use of
distal bypass grafting revascularization in diabetic patients
with ischemic ulcers. They showed a progressive increase in
the bypass/amputation ratio comparing outcomes of pa-
tients from 1984 to 1990. A retrospective evaluation was
reported of two groups of patients followed-up before and
after implementing diabetic foot care with a team approach
that focused on aggressive early intervention and extensive
use of surgical revascularization. LoGerfo et al15 showed a
reduction in major amputations, overall length of stay, and
total cost of care. The authors, however, pointed out that
Medicare reimbursement was inadequate to cover all the
procedures.
The widespread use of endovascular revascularization
techniques has further broadened the spectrum of revascu-
larization options for diabetic patients with critical leg
ischemia. A prospective study of peripheral angioplasty at
both proximal and distal levels showed an excellent limb
salvage rate, with only 10 of 191 patients (5.2%) undergo-
Table I. Synopsis of studies evaluating the direct cost of d
First author Study type Study population
Holzer, 1998 Retrospective analysis
of private insurance
claims
3013 subjects
Study period: 1991-1992
Age: 18-64 y
3524 ulcer episodes
Harrington,
2000
Retrospective analysis
of Medicare claims
400,000 Medicare
beneficiaries with DFU
Study period: 1995-1996
Ramsey,
1999
Retrospective case-
control study in
HMO
8905 subjects
Study period: 1992-1995
Age 18 y
541 foot ulcers
Apelqvist,
1994
Prospective study 314 subjects with DFU
Subjects followed-up thr
their ulcer episode
Stockl, 2004 Retrospective claims
data analysis
2253 subjects
Study period: 2000-2001
DFU, Diabetic foot ulcer; HMO, health maintenance organization; SNF, sk
aAttributable cost of DFU has been calculated as the difference between ave
and the expenditures the year before DFU diagnosis.ing a major amputation.16 Whether an open surgical or anendovascular procedure should be the first-line treatment
for diabetic patients with critical leg ischemia is still a matter
of debate and so is which of these two procedures might
represent the most cost-effective treatment. Regardless of
the procedure type, aggressive and effective revasculariza-
tion is crucial in limb salvage, particularly in amputation
reduction, an important driver of cost.
Many studies have now shown that a team approach to
diabetic foot conditions is effective in amputation preven-
tion. Zayed et al17 reported results of a retrospective anal-
ysis of 312 patients with diabetes and critical leg ischemia
and demonstrated a reduction in amputation rate in a
multidisciplinary setting. The team was composed of a
vascular and podiatric surgeon, diabetologist, tissue viabil-
ity nurse, interventional radiologist, and a radiology coor-
dinator.
A retrospective study from Sweden18 showed a 78%
decrease in major amputations after the implementation of
amultidisciplinary program for themanagement of diabetic
foot patients. A prospective study of a United States popu-
lation showed that podiatry-vascular surgery collaboration
tic foot patients
Results Notes
Average ulcer episode cost:
$4595
1. Primary healing: $1929
2. Healing by amputation:
$44,790
Grade 1 or 2 ulcers cost:
$1929
Grade 3 ulcers cost: $3980
Grade 4 or 5 ulcers cost:
$15,792
Severity grading according to
Wagner classification as 1
or 2; 3; 4 or 5
Aggregate disease attributable
cost: $1.45 billion
Average ulcer-related cost/
year: $3609
Medicare spending among
ulcer patients/y: $15,309
All Medicare spending among
all Medicare patients/y:
$5266
Excess cost for ulcer patients:
73.7% inpatient
10.9% outpatient
11.4% home health
4.0% SNF/hospice
Average cost of ulcer episode
over 1 year: $26,490
Total attributable cost of
DFU: $27,987a
Ulcer patients had more
inpatient days and more
emergency department
visits over the study period
Average ulcer episode cost:
1. Primary healing: $6664
2. Healing by amputation:
$44,790
Cost for ulcer patients:
61% inpatient
39% outpatient
Average ulcer episode cost:
$13,179
Grade 1 ulcers: $1892
Grade 2 ulcers: $4345
Grade 3 ulcers: $12,255
Grade 4 or 5 ulcers: $27,721
Severity grading according to
Wagner classification as 1;
2; 3; 4 or 5
77% inpatient cost
urse facility.
xpenditures for DFU patients over the first and second years after diagnosisiabe
s
ough
illed nresulted in 83% limb salvage at 5 years.19
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multidisciplinary team to prevent amputations reduction.
During a 4-year period, there was an 82% reduction in
major amputations. A prospective study from the United
Kingdom showed a 62% reduction in major amputations
and a 40% decrease in all amputations during an 11-year
period after a diabetic foot care service was started.22 Im-
plementation of existing guidelines is likely to lower ampu-
tation rates.
Results from a prospective study at a specialized dia-
betic foot clinic in Italy showed that implementing the
International Consensus on the Diabetic Foot recommen-
dations resulted in a decrease in major amputations from
10.7 per 100,000 inhabitants at the beginning of the study
to 6.24 per 100,000 inhabitants after 5 years. This decrease
was paired with a progressive increase in minor amputa-
tions.23 The authors also documented a progressive exten-
sive referral to the diabetic foot service during the study
period. This aspect is of particular interest because it shows
that improving provider education about diabetic foot dis-
ease may also improve more appropriate referral patterns.
COST EFFECTIVENESS OF INTERVENTIONS
Few studies have addressed the economic benefits of
interventions for the prevention and treatment of diabetic
foot disease. Most studies explore results from predictive
models, with the most common being the Markov model.
This can be a useful mathematic tool for obtaining a pro-
jection of cost and effects of an intervention. This method
for modeling disease, such as diabetic foot ulcers, is relevant
because it can take into account both the chronicity of the
disease and the occurrence of the same events more than
once.24 However, data from these studies are difficult to
compare due to differences in demographics and health
care systems.
A model to evaluate the effects of different types of
interventions on economic outcomes in a theoretic cohort
of 10,000 diabetic patients25 showed that prevention and
appropriate management of diabetic foot patients might
avoid up to 50% of amputations. The authors estimated
that educational intervention, a multidisciplinary team ap-
proach, and therapeutic footwear coverage could avoid
72%, 47%, and 53% of amputations, respectively. This
translates to $1,100,000, $750,000, and $850,000 in po-
tential savings over 1 year for each intervention. The au-
thors concluded that prevention, a multidisciplinary team
approach, and therapeutic footwear could save from
$2,900 to $4,442 in per patient costs. These United States
data strongly indicate a cost-savings from the initiation of
preventive strategies in the management of diabetic foot
patients in concert with a multidisciplinary team approach.
Apelqvist et al24 analyzed 5 years of cost-utility data
from preventive interventions on patients with diabetic foot
ulcers. The study focused on implementation of guidelines
from the International Working Group on Diabetic Foot
(IWGDF) and sought to demonstrate that the costs of
implementing a preventive system would be offset by the
benefits of amputation prevention.24 This study showedthat an intensive prevention strategy composed of patient
education, foot care, and therapeutic footwear is cost-
effective in a Swedish population, if the risk of foot ulcers
and amputations can be reduced by 25%.
Another European study used aMarkovmodel to assess
the potential economic effects of two interventions in pa-
tients with diabetic foot ulcers: intensive glycemic control
and optimal foot care as defined by IWGDF guidelines,
taken singularly or coupled vs standard of care without
guidelines implementation.26 The study showed that the
greatest reduction in amputation would have been achieved
with the combination of the two interventions. The most
favorable cost-effectiveness ratio was strongly linked to
ulcer prevention. The increased costs for guideline imple-
mentation were associated with less than $25,000 per
quality-adjusted life-years gained (1999 currency) provided
a reduction of 40% in amputations was obtained.
Management of the diabetic foot according to
guideline-based care improves survival, reduces diabetic foot
complications, is cost-effective, and even cost-saving com-
pared with usual care. Thus, policy makers and clinicians
working in the field of diabetic foot management should
see the cost of guidelines implementation as an attractive
option.
The effect of a staged management diabetic foot pro-
gram has been retrospectively evaluated in a sample of 169
patients from a public hospital system.27 In this study, 454
patients received regular foot care visits; patient education
and footwear were compared with 169 patients receiving
none of these services. During a 12-month period, the
diabetic foot care approach cohort had fewer hospitaliza-
tions, amputations, and emergency department visits for
foot-related problems; outpatient visits increased. These
improvements in outcomes translated into differences in
charges between the two groups of $4776 vs $5411 per
patient, with a savings of $635 per patient with access to a
foot and ankle specialist. Studies evaluating the cost-
effectiveness of interventions for the management of dia-
betic foot patients are summarized in Table II.
Matricali et al28 conducted a recent systematic review
on the health economics of diabetic foot care in the context
of a multidisciplinary setting. They found that the team
approach seems to be cost-effective, with the greatest ben-
efits expected over the long-term. The authors recom-
mended that policy makers should be particularly focused
on reimbursement for preventive and early intervention, as
well as for limb salvage procedures.
CONCLUSIONS
Extensive patient education, early assessment, and ag-
gressive treatment by a multidisciplinary team represent the
best approach to manage high-risk patients with diabetes.
Clinical and economic outcomes demonstrate reduced am-
putations, length of stay, and costs. The team must con-
tinue to become more effective, especially regarding early
cost-effective use of appropriate care, interventions, and
appropriate consultations to specialized teams. Early recog-
nition and prevention of diabetic foot disease has been
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States; however, limb preservation services are frequently
consulted very late in the disease process, after significant
pathology has progressed.
It is quite clear that by using an interdisciplinary team,
we can improve function and reduce amputation, but what
are the costs? Future clinical research might incorporate
specific evidenced-based pathways to reduce amputation
while choosing the most cost-effective diagnostic and treat-
ment options. The next step is to break down silos of care
between the various care settings, to improve the contin-
uum of care while realizing more productive and cost-
effective methods for saving limbs, and caring for our
high-risk population.
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